Megan K Reed1, Alexis M Roth2, Loni P Tabb2, Ali K Groves2, Stephen E Lankenau2. 1. Thomas Jefferson University, Department of Emergency Medicine, 1025 Walnut Street, College Building, Philadelphia, PA 19107, United States. Electronic address: megan.k.reed@jefferson.edu. 2. Drexel University, Dornsife School of Public Health, 3215 Market Street, Philadelphia, PA 19104, United States.
Abstract
BACKGROUND: Fentanyl dominates the heroin supply in many regions of the United States. One harm reduction response has been the distribution of fentanyl test strips to people who use heroin to test for the presence of fentanyl. Reports increasingly indicate that fentanyl contamination is occurring in the illicit stimulant market, but whether people who use stimulants would use fentanyl test strips is unknown. METHODS: Between January 2019 and January 2020, fifteen people in Philadelphia, PA who reported stimulant use completed a semi-structured interview with questions about their perceptions of fentanyl and willingness to use fentanyl test strips. Data were coded and analyzed for thematic content using constructs from the Health Belief Model and risk environment theory. RESULTS: Participants primarily reported using crack cocaine or crack cocaine/heroin, while some used methamphetamine, powder cocaine, or prescription opioids. All were aware of fentanyl and believed they were susceptible to a fentanyl overdose as stimulant users. Participants perceived benefits of using test strips but reported barriers, such as the unpredictable nature of buying or using drugs and not wanting to delay drug use to test. Structural conditions impeded participant actions to reduce overdose risk if their drugs tested positive for fentanyl. CONCLUSION: Fentanyl test strips were a desired harm reduction tool by many participants who used stimulants. In addition to providing access to the strips, programs should tailor overdose prevention education to these clients by acknowledging susceptibility, amplifying benefits, and addressing drug-specific barriers to use of fentanyl test strips.
BACKGROUND: Fentanyl dominates the heroin supply in many regions of the United States. One harm reduction response has been the distribution of fentanyl test strips to people who use heroin to test for the presence of fentanyl. Reports increasingly indicate that fentanyl contamination is occurring in the illicit stimulant market, but whether people who use stimulants would use fentanyl test strips is unknown. METHODS: Between January 2019 and January 2020, fifteen people in Philadelphia, PA who reported stimulant use completed a semi-structured interview with questions about their perceptions of fentanyl and willingness to use fentanyl test strips. Data were coded and analyzed for thematic content using constructs from the Health Belief Model and risk environment theory. RESULTS: Participants primarily reported using crack cocaine or crack cocaine/heroin, while some used methamphetamine, powder cocaine, or prescription opioids. All were aware of fentanyl and believed they were susceptible to a fentanyl overdose as stimulant users. Participants perceived benefits of using test strips but reported barriers, such as the unpredictable nature of buying or using drugs and not wanting to delay drug use to test. Structural conditions impeded participant actions to reduce overdose risk if their drugs tested positive for fentanyl. CONCLUSION: Fentanyl test strips were a desired harm reduction tool by many participants who used stimulants. In addition to providing access to the strips, programs should tailor overdose prevention education to these clients by acknowledging susceptibility, amplifying benefits, and addressing drug-specific barriers to use of fentanyl test strips.
Authors: Scott Burris; Kim M Blankenship; Martin Donoghoe; Susan Sherman; Jon S Vernick; Patricia Case; Zita Lazzarini; Stephen Koester Journal: Milbank Q Date: 2004 Impact factor: 4.911
Authors: Jill Owczarzak; Noelle Weicker; Glenna Urquhart; Miles Morris; Ju Nyeong Park; Susan G Sherman Journal: Health Place Date: 2020-07-22 Impact factor: 4.078
Authors: Leah LaRue; Robert K Twillman; Eric Dawson; Penn Whitley; Melissa A Frasco; Angela Huskey; Maria G Guevara Journal: JAMA Netw Open Date: 2019-04-05
Authors: Anthony J Tomassoni; Kathryn F Hawk; Karen Jubanyik; Daniel P Nogee; Thomas Durant; Kara L Lynch; Rushaben Patel; David Dinh; Andrew Ulrich; Gail D'Onofrio Journal: MMWR Morb Mortal Wkly Rep Date: 2017-02-03 Impact factor: 17.586
Authors: Joseph J Palamar; Linda B Cottler; Bruce A Goldberger; Stevan Geoffrey Severtson; David J Grundy; Janetta L Iwanicki; Daniel Ciccarone Journal: Am J Drug Alcohol Abuse Date: 2022-06-15 Impact factor: 3.912
Authors: Madeline C Frost; Elizabeth J Austin; Maria A Corcorran; Elsa S Briggs; Czarina N Behrends; Alexa M Juarez; Noah D Frank; Elise Healy; Stephanie M Prohaska; Paul A LaKosky; Shashi N Kapadia; David C Perlman; Bruce R Schackman; Don C Des Jarlais; Emily C Williams; Sara N Glick Journal: Harm Reduct J Date: 2022-07-19
Authors: Wendy Masterton; Danilo Falzon; Gillian Burton; Hannah Carver; Bruce Wallace; Elizabeth V Aston; Harry Sumnall; Fiona Measham; Rosalind Gittins; Vicki Craik; Joe Schofield; Simon Little; Tessa Parkes Journal: Int J Environ Res Public Health Date: 2022-09-22 Impact factor: 4.614